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Glioblastoma (GBM) is the most frequent and malignant brain
tumor classiﬁed as grade IV by the World Health Organization (Louis
et al., 2007) and accounts for 52% of all gliomas. The current treatment
combines surgical debulking with chemotherapy and radiotherapy,
however, the patients' survival remains very low (Stupp et al., 2005),
emphasizing the need for continued search for novel and effective
therapies. Identifying molecular markers that associate with beneﬁcial
patient survival is critical for highlighting important biological process-
es involved in disease progression andmay guide the search for innova-
tive therapies.
For a long time the brain was considered an immune privileged
organ due to the presence of the blood brain barrier (BBB), lack of lym-
phatic drainage and of professional antigen presenting cells (APCs).erms of the Creative Commons
which permits non-commercial
d the original author and source
earch Group, Jonas Lies vei 91,
7 55586360.
Chekenya).
lished by Elsevier B.V. All rights reserTherefore, brain tumorswere consideredprotected from immune surveil-
lance. However, recent investigations showed that activated immune
cells can cross the BBB (Becher et al., 2000; Sehgal and Berger, 2000;
Alter et al., 2003; Prendergast and Anderton, 2009), which is also often
disrupted at the tumor site, and that microglia can act as resident APCs
(Becher et al., 2000; Yang et al., 2010a). Thus, the role of the immune
system in brain cancer has become a subject of intensive study. It has
been shown, that the immune cells perform anti-tumor surveillance
and display potential for killing the tumor cells (Costello et al., 2002;
Tang et al., 2005; Carpentier andMeng, 2006;Ueda et al., 2007). However,
GBM develops multiple escape mechanisms, such as expression of inhib-
itory molecules (Rouas-Freiss et al., 2005; Gomez and Kruse, 2006;
Malmberg and Ljunggren, 2006; Zhang, 2010) and release of soluble
immunosuppressive factors (Zou et al., 1999; Gomez and Kruse, 2006;
Malmberg and Ljunggren, 2006). Moreover, the role of the immune
system in cancer is ambiguous, as there exist immune cell subpopulations
that promote tumor progression (de Visser et al., 2006; Fecci et al., 2006;
Wang, 2008;Ostrand-Rosenberg and Sinha, 2009) and that are thought to
be induced by the tumor cells. There is no consensus on the impact of
tumor immune inﬁltration on the patient's overall outcome, nor are the
mechanisms involved in the patients' systemic response to the tumor
delineated.ved.
Table 1
Fluorochrome-conjugated antibodies used for PBMCs and GBM phenotyping. The
antibodies were purchased from: BD Biosciences, Franklin Lakes, NJ; Invitrogen,
Paisley, UK; eBioscience San Diego, CA; BioLegend, San Diego, CA; ImmunoTools
(Friesoythe, Germany); and R&D Systems Abingdon, UK.
Antibody Manufacturer
PE-CD152 (CTLA-4) BioLegend
PE-TexasRed-CD56 Invitrogen
PerCP-Cy5.5-CD25 eBioscience
PE-Cy7-CD4 BD Biosciences
Alexa647-CD127 BD Biosciences
Alexa700-CD62L BioLegend
Alexa750-CD8 Invitrogen
V450-CD8 BD Biosciences
Paciﬁc orange-CD45 Invitrogen
PE-HLA-A,B,C BD Biosciences
PE-Dy647-CD19 ImmunoTools
PerCP-Cy5.5-CD45 BD Biosciences
PE-Cy7-CD31 BioLegend
PE-Dy747-CD4 ImmunoTools
APC-CD25 BD Biosciences
V450-CD80 BD Biosciences
V450-CD86 BD Biosciences
V450-CD27 BD Biosciences
V450-CD40 BD Biosciences
V450-CD73 BD Biosciences
Paciﬁc Blue™-CD154 BioLegend
V450-CD31 BD Biosciences
V450-CD56 BD Biosciences
V500-CD3 BD Biosciences
Brilliant Violet 570™-CD4 BioLegend
FITC-CD28 BD Biosciences
Alexa Fluor® 488-MICA R&D Systems
FITC-CD62L BD Biosciences
FITC-ILT2 R&D Systems
FITC-ILT3 R&D Systems
FITC-ILT4 R&D Systems
FITC-CD95 BD Biosciences
FITC-CD16 BD Biosciences
FITC-TCR Vα24-Jα18 (iNKT cell) BioLegend
PE-MICB R&D Systems
PE-CD70 BD Biosciences
PE-CD39 BioLegend
PE-HLA-G eBioscience
PE-HLA-E eBioscience
PE-CD178 (Fas-L) BioLegend
PE-NKG2D R&D Systems
PE-CD1d BioLegend
PE-CF594-CD14 BD Biosciences
PerCP-Cy5.5-CD45 BD Biosciences
PE-Cy7™-CD8 BD Biosciences
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patients and identiﬁed several coordinated mechanisms of tumor-
driven immune suppression. A substantial number of functional studies
describing tumor-immune interactions focused only on particular
subpopulations andmarkers. The aim of ourworkwas to broadly inves-
tigate the immune contexture of GBM patients both within the tumor
microenvironment and at the systemic level. We highlight the coordi-
nated anti-tumor immune responses and tumor-mediated immune
escape mechanisms. Our results demonstrated a signiﬁcant positive
correlation of increased CD3+ and CD8+ cellular inﬁltration into
the tumor with improved patient survival. The major mechanisms
of tumor immune escape in GBM patients were (1) induction of
CD8+CD28−Foxp3+ Tregs, that could mediate the tolerization of
APCs by upregulating immunoglobulin-like transcript (ILT) inhibitory
receptors and downregulating CD80, CD86 and CD40 costimulatory
molecules (Fecci et al., 2006) and high surface expression of CD73
that could lead to T-cell suppression (Jeffes et al., 1993; Purdy and
Campbell, 2009; Hausler et al., 2011). Comparison between the GBM
patients' and healthy donors' PBMCs and plasma also revealed systemic
immunosuppression. Thus, detailed characterization of the patients'
immune status is required for design of appropriate immunotherapy
for GBM.
2. Materials and methods
2.1. Blood and tumor material
Patients' blood and GBM biopsies were obtained during surgical
resections performed at the Haukeland University Hospital, Norway,
between 2009 and 2011. The patients gave their written informed con-
sent and the studywas approved by the Norwegian regional Helse-Vest
ethical board. Parts of the tumor were formalin ﬁxed and parafﬁn
embedded (FFPE). H&E-stained sectionswere prepared to deﬁne repre-
sentative tumor regions and the neuropathologists at the department of
pathology, Gades Institute, Haukeland University Hospital routinely
conﬁrmed GBM diagnosis according to the World Health Organization
(WHO) classiﬁcation (Louis et al., 2007). Furthermore, patients diag-
nosed with GBM had routine follow-upwithMRI interpreted by neuro-
radiologists at the department of radiology, Haukeland University
Hospital, as part of their routinemanagement. Eligibility criteria includ-
ed availability of follow-up data, less than 50% necrosis in the sample,
and only biopsies obtained at primary diagnosis were included. Clinical
information was obtained by reviewing the medical records, and death
certiﬁcates/registers. Patients were followed-up from the date of oper-
ation until death or December 2012. The median follow-up of the
seven patients that were alive was 30 months, range 23–39 months.
All patients were treated by surgery, radiotherapy and/or chemothera-
py and survival determined as the time elapsed from the date of surgery
to the date of death.
Part of the fresh tissuewas dissociated by use of Neural TissueDisso-
ciation Kit as recommended by the manufacturer (Miltenyi Biotec,
Bergisch Gladbach, Germany). Cell suspension was frozen in 10%
DMSO (Sigma, St. Louis, MO) and 10% fetal bovine serum (FBS) (PAA,
Pasching, Austria) solution according to standard protocol. Peripheral
blood was collected using BD Vacutainer® CPT™ Cell Preparation Tube
with Sodium Citrate (BD Biosciences, Franklin Lakes, NJ) and Peripheral
Blood Mononuclear Cells (PBMCs) were isolated and frozen as above.
Patients' plasmawas stored at−20 °C., PBMCs and plasmawere isolat-
ed from age and gender matched healthy donors (Table S1) using the
same method.
2.2. Immunohistochemistry
FFPE tissuewas subjected to immunohistochemistry using the avidin–
biotin–peroxidase complex method according to themanufacturer's pro-
tocol (Vectastain, Vector laboratories, Burlingame, CA). FFPE sectionsfrom 65 patients were immunolabeled with rabbit anti-human CD3
(Dako, Glostrup, Denmark), mouse anti-human CD4 (Novocastra™ Leica
Microsystems GmbH, Wetzlar, Germany) and mouse anti-human CD8α
(Dako) primary antibodies according to standard protocols. Human tonsil
tissue was used for positive control and staining with irrelevant primary
antibody (MOC-31, Santa Cruz Biotechnology, Santa Cruz, CA) as nega-
tive control. CD3+ cells were quantiﬁed bymorphometry and the result
presented as percentage of total number of cells. Area fractions (%) of
CD4+ and CD8+ cells were quantiﬁed on 89,400 μm2 ﬁeld of view
(magniﬁcation 400×), minimum of 4 fragments, representing hot
spots, per each section and were analyzed, using NIS-Elements BR v4
software (Nikon).2.3. Bisulﬁte treatment and MGMT methylation analysis
For the analysis ofMGMTpromotermethylation, DNAwas extracted
from snap-frozen tumor tissue using the QIAamp DNEasy mini kit
(Qiagen, Hilden, Germany). Bisulﬁte conversion was conducted as pre-
viously described (Mikeska et al., 2007).
Fig. 1. Immune cell inﬁltration into the tumor microenvironment. A. Representative IHC staining of GBM biopsy: 1, 2: CD3 staining— patients with high and low numbers of CD3 positive
cells; 3, 4: CD8 staining— patients with high and low numbers of CD8 positive cells; 5, 6: CD4 staining— patients with high and low numbers of CD4 positive cells; B and C. Kaplan–Meier
survival curves of CD3+ and CD8+ cell inﬁltration with patients' % survival time in months. D. Covariance of CD3+, CD8+ and CD4+ cells. Magniﬁcation 400×, scalebar in A6 50 μm.
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2.4.1. PBMCs and GBM tumor phenotyping
PBMCs/GBM cells were thawed, counted, and washed with PBS
containing 0.5% BSA and 2% mouse serum. Surface stainings were
performed according to standard protocol with different combina-
tions of ﬂuorochrome-conjugated mouse anti-human antibodies
present in Table 1. Proper isotype controls were used to exclude
unspeciﬁc antibody binding. PBMCs were stained with LIVE/DEAD®
Fixable Blue Dead Cell Stain Kit (Invitrogen, Paisley, UK) and GBMcells with LIVE/DEAD® Fixable Near-IR Dead Cell Stain Kit (Invitrogen)
according to manufacturer's instructions. PBMCs were then ﬁxed and
permeabilized with Foxp3/Transcription Factor Staining Buffer Set
(eBioscience San Diego, CA) and stained with eFluor450-conjugated
anti-human Foxp3 (eBioscience) and PE-CD152 (CTLA-4) (BioLegend,
San Diego, CA) according to manufacturer's recommendations. GBM
cells were ﬁxed and permeabilized with Cytoﬁx/Cytoperm (BD
Biosciences), washedwith Perm/Wash buffer (BD Biosciences) contain-
ing 2% mouse serum and stained for intracellular markers with PE-
CD152 (CTLA-4) (BioLegend) and PE-Foxp3 (BD Biosciences). For better
Fig. 2. (A) Kaplan–Meier % survival curves and observation time in months of the
whole patient group (n = 65). Median survival with censored patients, median ±
SEM (95% CI) 11.7 ± 0.8(10–13.4). (B) Cumulative survival by MGMT status (p = 0.093).
(C) Kaplan–Meier % survival by post-operative treatment (p = 0.0001).
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sample was stained with Hoechst (Sigma) or TO-PRO®-3 iodide
(Invitrogen) for 10 min or 2 min, respectively, before data acquisition.
Data were acquired using BD FACSAria and BD LSRFortessa ﬂow
cytometers and data analyzed with BD FACSDiva Software v6.2 (BD
Biosciences Franklin Lakes, NJ).
2.4.2. Gating strategy applied to PBMC phenotyping
Debris and dead cells were gated based on size on FSC vs. SSC
channels and Live/Dead staining and excluded from the analysis.
Doublets were excluded based on SSC-A vs. SSC-H plot. T-cell popula-
tion was gated based on the FSC and SSC parameters and surface ex-
pression of CD3. Two main populations of T-cells were gated: CD4+
(helper T-lymphocytes, Th) and CD8+ (cytotoxic T-lymphocytes, CTLs)
and CD4+ (helper T-lymphocytes, Th). Naturally occurring regulatory
T-cells (Tregs) were deﬁned as CD4+CD25highFoxp3+ cells (Fig. 3H). As
additional markers conﬁrming this identiﬁcation, CD152 and CD127
were used (Hartigan-O'Connor et al., 2007) (Fig. 3H).2.4.3. Gating strategy applied to GBM biopsy phenotyping
Dead cells were excluded from the analysis based on Live/Dead
staining (Fig. S1C). We used Hoechst or TO-PRO®-3 iodide staining on
ﬁxed and permeabilized cells in addition to FSC and SSC parameters to
include in our analysis only nucleated cells (Fig. S1B). Doubletswere ex-
cluded based on SSC-A vs. SSC-H plot. Tumor inﬁltrating-immune cells
were deﬁned as CD45+ cells (Fig. S1C). The population of CD45-cells
was investigated for the presence of endothelial cells based on CD31
expression. Only 2.288% ±0.9889 of all CD45− cells expressed CD31;
therefore, we deﬁned the CD45 negative fraction as tumor cell enriched.
In each stainingwithin CD45+ cells, the following subpopulations of im-
mune cells were distinguished: T-cells gated as small (FSC parameter),
CD3+, CD8+ (CTLs) and CD4+ (Th) events (Fig. S1F, G, H). Monocytes/
macrophages/dendritic cells were gated based on FSC and SSC parame-
ters (Fig. S1F) and henceforth designated antigen presenting cells
(APCs) in the text. In additional stainings, B-cells were deﬁned as
small, CD3−CD19+ cells, NK cells gated as CD3−CD14−CD56+ cells
and 3 different Tregs subpopulations deﬁned as CD4+CD25highFoxp3+,
CD8+CD28−Foxp3+, and CD8+CD25+Foxp3+. We also examined
T-cell population for the expression of TCR Vα24-Jα18 — a marker
for type I natural killer T-cells.
2.4.4. Plasma analysis — Cytometric Bead Array (CBA)
Concentration of 16 proteins was measured with CBA technique in
plasma samples from GBM patients and in age- and gender-matched
healthy donors. We used Human Soluble Protein Master Buffer Kit (BD
Biosciences), Human Flex Sets according to themanufacturer's protocol
(BD Biosciences) listed in Table 4 and Human TGF-β1 Single Plex Flex
Set (BD Biosciences). Data were acquired on BD Canto and BD
LSRFortessa ﬂow cytometers and analyzed with FCAP Array Software
(Soft Flow Inc., Pecs, Hungary).
2.5. Statistics
Patient survival was estimated using the Kaplan–Meier method
(Kaplan and M.P., 1958) and compared between groups with the
log rank test (Mantel, 1966). Univariate analyses were performed
to identify variables with signiﬁcant prognostic impact (p b 0.05)
and, these variables were further included in the Cox proportional
hazards model. Backward stepwise selection was applied to select
variables to adjust for effects of potential confounding variables in-
cluding age (0–10, 10–20, 20–30, 30–40, 40–50, 50–60, 60–70, 70–
80 years) and post-operative treatment, CD3 (grouped 0–10,
10–20, 20–30, 30–40), CD8 and CD4 (grouped 0–1, 1–2, 2–3) gender
and MGMT as categorical variables. To compare the patient and
healthy donor group the non-parametric Wilcoxon signed rank test
was used. When comparing more than two cell populations within
patient GBM or between patients and donors we used One-Way
ANOVA tests (Friedman and Kruskal–Wallis, respectively). In
all analyses probability values less or equal to 0.05 were considered
signiﬁcant. Descriptive statistics are reported as mean, mean ± stan-
dard error of the mean (SEM). All statistical analyses were performed
with the (SPSS) v11.0 software.
3. Results
3.1. Increased tumor inﬁltration of CD3+ and CD8+ cells correlates with
prolonged patient survival
Analysis of CD3, CD4 and CD8 expressing cells in 65 GBM biopsies
revealed a great heterogeneity in the amounts and their spatial local-
ization, both between and within the patients' tumors (Fig. 1A). In
some cases the immune cells were localized in hotspots in the vicin-
ity of blood vessels and/or inﬁltrated the entire tumor (Fig. 1A). To
determine the impact of the degree of inﬁltration of immune cells
on tumor progression, we quantiﬁed the CD3+, CD4+ and CD8+
Table 2
Survival, patient clinical parameters and statistical signiﬁcance.
Variable n Median
survival
± SEM
(months)
95% CI
(months)
p-Value
Log Rank
Mantel–Cox
p-
Value
Cox
Gender 0.37
Males 35 13.0 ± 1.4 (10.3–15.8)
Females 30 9.5 ± 1.8 (5.8–13.1)
Age 0.028 0.010
b10 1 12.6
20–30 2 12.4
30–40 5 18.3 ± 1.7 (14.9–21.7)
40–50 7 18.8 ±
13.1
(0–44.6)
50–60 17 16.3 ± 2.5 (11.3–21.3)
60–70 26 8.7 ± 22 (4.2–13.2)
70–80 7 8.5 ± 3.1 (2.4–14.6)
MGMT 0.093
Unmehtylated 33 11.5 ± 1.5 (8.3–14.6)
Methylated 24 10.4 ± 1.5 (0.5–30.3)
Pre-Op steroids 0.268
Unknown 14 12.6 ± 3.0 (6.6–18.5)
1 day 14 12.4 ± 0.6 (11.13–13.7)
2–7 days 19 9.5 ± 2.3 (4.9–14.1)
8–14 days 11 17.0 ± 3.6 (9.8–24.2)
Over 14 days 7 6.5 ± 0.4 (5.6–7.3)
CD4
b10% 56 11.3 ± 1.2 (8.8–13.8) 0.526
10–20% 4 12.4 ± 4.4 (3.8–21.1)
20–30& 2 6.5
CD8 0.062 0.027
b1% 56 11.3 ± 1.2 (9.0–13.7)
1–2% 4 39.0 ± 0
2–3% 3 13.0 ± 5.8 (1.5–24.5)
CD3 0.022 0.024
b10% 36 6.5 ± 1.7
10–20% 20 5.9 ± 1.4
20–30% 4 17.1
N30% 1
Post-op treatment 0.0001
None 5 2.4 ± 1.6 (0–5.7)
IR only 9 10.4 ± 2.9 (4.9–16.0)
Chemo + IR (TMZ ±
other + radiation
+ additional)
51 13.3 ± 1.9 (9.4–17.2)
The p-values in bold are those that are statistically signiﬁcant.
a Median survival and 95% conﬁdence interval, in months.
b Patient age was used as continuous variable for the Cox-regression model.
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expression with the patients' outcome. The mean and the median
survival of the patient population were 19.6 ± 1.8 and 11.7 ±
0.8 months respectively (Fig. 2A). Mean and median survival of fe-
males were 13.8 ± 2 and 9.5 ± 1.8 months respectively, compared
to males 16.4 ± 1.9 and 9.8 ± 1.4 months respectively, (Table 2).
In univariate analyses, gender had no signiﬁcant impact on patients'
survival, Log Rank (Mantel–Cox) Chi-square 0.77, df = 1, p = 0.37.
Althoughmethylation of the methyl guanine DNAmethyltransferase
(MGMT) gene promoter is established as predictive of response to
temozolomide chemotherapy (Hegi et al., 2005; Stupp et al., 2009),
reports of its prognostic role have been variable (Costa et al.,
2010). In our material, MGMT promoter methylation was not signif-
icantly associated with patient survival, Log Rank (Mantel–Cox)
Chi-square 2.82, df = 1, p = 0.093 (Fig. 2B and Table 2). Pre-
operative treatment with steroids had no effect on outcome, Log
Rank, Chi-square 5.196, df = 4, p = 0.268 (Table 2). Age at diagno-
sis was a signiﬁcant prognostic factor, Log Rank (Mantel–Cox) Chi-square
14.11 df = 6, p = 0.028. Post-operative treatment had a signiﬁcant
effect on overall survival, p = 0.0001, (Table 2). Quantiﬁcation of CD3+
immune cell inﬁltrates revealed a correlation of increased CD3+ T-cell
inﬁltration with longer survival, Log Rank, Chi-square 9.58, df = 3,
p = 0.022, (Fig. 1B). There was a trend for CD8, Log Rank, Chi-square
5.56 df = 2, p = 0.062, and no association of CD4+ immune inﬁltrates
with overall patient survival, Log Rank, Chi-square 1.28, df = 2, p =
0.52. To investigate whether increased CD3+ and CD8+ cells were inde-
pendent prognostic factors we corrected for age, MGMT status and
post-operative treatment using backward, stepwise Cox regression
analysis. Increased CD8+ immune cell inﬁltrates were then associated
with longer survival independent of age at diagnosis, Chi-square 4.87,
df = 1, p = 0.027. Increased CD3+ T cell inﬁltration was associated
with longer survival independent of age, and post-operative treatment,
p = 0.027. Moreover, CD3+ immune inﬁltrates were signiﬁcantly corre-
lated with CD8+ cells, (Pearson correlation 0.579, p b 0.0001, n = 59)
and with CD4+ cells, (Pearson correlation 0.47, p b 0.0001 n = 59),
(Fig. 1D and Table S2).
3.2. Patients' T cells present a suppressed phenotype within the tumor mi-
croenvironment and a moderate immunosuppression was observed at the
systemic level
To identify the phenotype of the tumor inﬁltrating immune cells
impacting patients' outcome, 8 patients' biopsies randomly selected
from the original cohort were dissociated and single cells analyzed
using multicolor ﬂow cytometry. We compared proportion and pheno-
type of tumor inﬁltrating T-cell subpopulations with paired patients'
peripheral T-cells and with 9 gender and age matched healthy donors'
T-cells. First, we observed that the proportion of Th in patients' blood
was signiﬁcantly diminished compared to normal donor (45.28% ±
7.20 and 65.68% ±2.10 of CD3+ cells, respectively, p = 0.0005, Fig. 3B
and Table 3) and there was a tendency for further diminution within
the tumor microenvironment (29.43% ±7.20 of CD3+ cells, Fig. 3B
and Table 3). However, no signiﬁcant differences in the percentage of
CTL cells were foundwhenwe compared the blood of patients to donors
and GBM biopsy (Fig. 3A and Table 3). No signiﬁcant difference was
observed in the expression of the co-stimulatory receptor CD28
(Fig. 3C, D and Table 3) and L-selectin CD62L (Fig. 3E, Table 3) in
patients' and donors' peripheral Th cells and CTLs, while it was down
regulated in tumor inﬁltrating Th cells and CTLs when compared to
patients' peripheral T cells (Fig. 3C, D, E and Table 3). Moreover, tumor
inﬁltrating CTLs displayed decreased expression of the adhesion
molecule CD56 when compared to patients' peripheral CTLs, while no
difference was observed comparing patients' vs. donors' peripheral
CTLs (Fig. 3F, Table 3). Signiﬁcantly more of patients' peripheral Th
cells compared to donors' expressed the inhibitory receptor CTLA-4,
however, there was a trend for diminutionwithin the tumor inﬁltratingTh (Fig. 3G, Table 3). Furthermore, we investigated the presence of Tregs
in 9 donors' and patients' peripheral blood and in 5 pairedGBMbiopsies.
The naturally-occurring CD4+CD25highFoxp3+ Tregs were not detected
among the tumor inﬁltrating immune cells in our GBM patients (data
not shown) and no difference was found in the proportions of these
Tregs within patients' vs. donors' peripheral T cells (Fig. 3I and Table 3).
However, in 60% (3/5) of the patients, CD8+CD28−Foxp3+ Tregs were
identiﬁed and represented 2.08% ±0.99 of all T-cells (Fig. 3J). They
were not detected in the blood of both patients and controls. In addition,
we examined the GBM biopsies for the presence of NK and B cells. They
were not very abundant and represented 2.11%±0.54 and 0.66%±0.27
(n = 8) of all tumor inﬁltrating immune cells, respectively. Within all
patients, NK cells were predominantly CD56dimCD16negative (Fig. 3K)
and 57.45% ±12.05 expressed the activating receptor NKG2D
(Fig. 3K). Six patients' biopsies were analyzed for the presence of type
I natural killer T-cells. However, they constituted only 1.13% ±0.65 of
all T-cells (data not shown).
3.3. Tumor inﬁltrating macrophages/microglia present immunotolerized
phenotypes
The tumor-induced population of CD8+CD28−Foxp3+ Tregs detect-
ed in our patients' biopsies has been reported to mediate immune
76 J. Kmiecik et al. / Journal of Neuroimmunology 264 (2013) 71–83
77J. Kmiecik et al. / Journal of Neuroimmunology 264 (2013) 71–83tolerization by up regulating the expression of inhibitory receptors:
immunoglobulin-like transcripts 2, 3, and 4 (ILT2, -3, -4) and down reg-
ulating the expression of co-stimulatory molecules CD40, CD80 and
CD86 on APCs (Wang, 2008). Therefore, we investigated the phenotype
of tumor inﬁltrating APCs (mainly macrophages/microglia). Remark-
ably, these cells represented the major subtype of immune cells in the
tumormicroenvironment, constituting 53.50%±4.30 (n = 8) of all im-
mune cells (Suppl Fig. 1 shows gating strategy). 13.21% ±6.90 of APCs
expressed CD4 and 21.49% ±4.16 expressed CD8 (n = 8, Fig. 4A and
B). Substantial proportions of APCs were positive for ILT2, ILT3 and
ILT4 (38.60% ±6.79; 43.25% ±6.35 and 28.79% ±4.66, respectively,
n = 8, Fig. 4A and C). Moreover, these cells highly expressed HLA-G
and HLA-E (40.34% ±5.93 and 61.11% ±4.72 of positive cells, respec-
tively, n = 8, Fig. 4A and D) that are ligands for ILTs and NKG2A inhib-
itory receptor. Only small proportions of APCs expressed CD40, CD80
and CD86 (12.61%±3.37, 4.14%±2.38 and 15.73%±4.12, respectively,
n = 8, Fig. 4E and F). On the other hand, we detected a proportion of
APCs expressing MHC class I – related chains A and B (MICA and
MICB) – ligands for the NKG2D activating receptor (26.53% ±6.60 and
8.39%±2.71 of all APCs, n = 8, respectively, Fig. 4E and G). Interesting-
ly, nearly half of APCs (46.58% ±9.54, n = 8, Fig. 4E and H) expressed
NKG2D.
3.4. Tumor inﬁltrating immune cells display impaired expression of
co-stimulatory molecules
Additionally, we investigated the tumor inﬁltrating immune cells for
expression of co-stimulatory ligands and receptors important for im-
mune function. Immune response can be stimulated upon binding of
CD40 expressed on APCs to its ligand CD154 expressed on activated T-
cells and some NK cells (Foy et al., 1996; Jyothi and Khar, 2000). Our
results show that in GBM biopsies 12.61% ±3.37 of APCs are CD40+
and all T-cells are CD154− (n = 8, Fig. 5A).We investigated the expres-
sion of CD27 and its ligand CD70 that are also involved in immune
modulation (Garcia et al., 2004). In our patient cohort, 33.49% ±4.00
of T-cells expressed CD70 whereas all T-cells were CD27− (n = 8,
Fig. 5B). Almost no T-cells expressed FasL (0.39% ±0.27 FasL+ of
all T-cells, n = 8, data not shown). However, the majority of CTLs
(82.75% ±3.30, n = 8, Fig. 5C) expressed NKG2D.
3.5. Tumor integrated mechanisms of immune escape vs. potential
immunogenicity
We analyzed the tumor cells for the expression of molecules poten-
tially involved in immune escape or immunogenicity. Our results show
that in all patients analyzed, the majority of tumor cells are positive for
HLA-A,B,C (93.26% ±1.85, n = 8, Fig. 6A and B). On the other hand,
only small proportions of tumor cells expressed HLA-G and HLA-E
(0.538% ±0.27 and 6.23% ±3.50, respectively, n = 8, Fig. 6A and B).
The tumor cells failed to expressMICB and CD70— ligands for activating
receptors present on immune cells. However, a proportion of tumor
cells were MICA positive (24.53% ±8.78, n = 8, Fig. 6A and C). We
also analyzed tumor cells for the expression of Fas and FasL. All tumor
cells were negative for FasL while 21.54% ±4.37 expressed Fas (n = 8,
Fig. 6A and D). Additionally, we examined both tumor and tumorFig. 3. Patients' T-cells are suppressed within the tumor microenvironment and at the systemi
tumor inﬁltrating T-cells (n = 8). B. Proportions of Th cells within donors' and patients' periph
grams showing expression of CD28 on CTLs (C) and Th cells (D) (CD28— ﬁlled histogram, isoty
peripheral (n = 9) and tumor inﬁltrating (n = 8) CTL cells (C) and Th cells (D). E. Proportion
(n = 8) CTL cells and Th cells. F. Proportions of CD56+ cells within donors' and patients' perip
donors' and patients' peripheral (n = 9) and tumor inﬁltrating (n = 8)Th cells. H. Gating strate
(Th cells) population, then on CD4+CD25high the Foxp3+ cells (Tregs) were gated (ﬁlled histogram
trol). The Tregs population identity was conﬁrmedwith the high expression of CTLA-4 and low e
solid line: isotype control, open histogramwith dashed line:markers' expression on CD4+CD25−
J. Representative plots showing CD8+CD28−Foxp3+ Tregs population present in the GBM biops
lymphocytes (left) were predominantly CD56dimCD16dim (right) and expressed NKG2D (bottoinﬁltrating immune cells for the expression of CD39 and CD73
ectonucleotidases that have been described to mediate immunosuppres-
sion of T cells (Hausler et al., 2011). In our patients, larger proportions of
tumor cells were positive for CD73 compared to APCs and T-cells (33.49%
±5.31 vs. 8.150% ±2.83 and 3.54 ± 0.90, respectively, n = 8, p N 0.05
and p = 0.0099, respectively, Fig. 6E). Contrasting results were obtained
for the CD39 molecule, which was highly expressed on APCs but not on
tumor cells (84.61% ±2.74 vs. 6.48% ±1.98, p = 0.0003, n = 8,
Fig. 6F). We also detected CD39+ T-cells (15.29% ±4.05, n = 8, Fig. 6F).
The tumor–immune cell interactions in the tumor microenvironment
are summarized schematically in Fig. 6G.
3.6. The cytokine balance in patients' plasma is anti-inﬂammatory com-
pared to healthy donors
We examined the concentration of 16 proteins in the patients' and
donors' plasma. The concentration of IL-10 was signiﬁcantly higher in
patients' plasma and there was a trend for decreased concentration of
IL-2 and IL-12 (Table 4). The concentrations of IL-5, MCP-1 and FasL
were signiﬁcantly lower compared to the healthy donors (Table 4).
There was no signiﬁcant difference in the concentration of other
proteins examined (Table 4). Unexpectedly, the mean levels of VEGF
in patients and donors were similar, contrary to other studies reporting
signiﬁcant increase of VEGF concentration in the plasma of brain tumor
patients (Sciacca et al., 2004). Inmost cases of both patients and donors,
TGFβ plasma levels were undetectable (data not shown).
4. Discussion
The aim of our work was to perform an integrated characterization
of GBMpatients' immune contexture bothwithin the tumormicroenvi-
ronment and at the systemic level. All research reports referring to
glioma immunity published so far present investigations focused on
particular subpopulations and markers. However, simultaneous analy-
sis of themultitude of immune defects in patientsmay help in designing
novel immunotherapies, more individualized treatments and pre-
empting possible escape mechanisms.
Contradictory reports exist (Dunn et al., 2007) regarding the prog-
nostic value of immune inﬁltrates in GBM patients. Several recent stud-
ies observed positive correlation of increased numbers of glioma
inﬁltrating lymphocytes with better patients' survival (Yang et al.,
2010b; Lohr et al., 2011; Kim et al., 2012), while some older reports de-
scribe negative (Safdari et al., 1985) or no correlation (Rossi et al., 1989).
These discordances could be related to different approaches used to
identify lymphocyte subpopulations. In our study, increased inﬁltration
of CD3+ immune cells in the tumormicroenvironmentwas signiﬁcantly
associatedwith patients' improved survival, independent of age at diag-
nosis, MGMT promoter hypermethylation and postoperative treatment.
Increased CD8+ immune cell inﬁltration was also signiﬁcantly associat-
edwith improved survival independent of age at diagnosis but not post-
operative treatment, while the level of CD4+ cell inﬁltrates did not
signiﬁcantly correlate with patient survival. CD3+ and CD8+ cells
were prognostic for a very small number of patients andmay be argued
to lack clinical relevance, however, the association of CD3+ cells with
almost double increased lifespan may underlie a very importantc level. A. Proportions of CTLs within donors' and patients' peripheral T-cells (n = 9) and
eral T-cells (n = 9) and tumor inﬁltrating T-cells (n = 8). C and D. Representative histo-
pe control— open histogram) and proportions of CD28+ cells within donors' and patients'
s of CD62L+ cells within donors' and patients' peripheral (n = 9) and tumor inﬁltrating
heral (n = 9) and tumor inﬁltrating (n = 8) CTLs. G. Proportions of CTLA-4+ cells within
gy for naturally occurring Tregs in peripheral blood: Gate CD4+CD25high cells on CD3+CD4+
s: Foxp3 expression on CD4+CD25high cells, open histogramswith solid line: isotype con-
xpression of CD127 (ﬁlled histograms:markers' expression on Tregs, open histogramswith
population). I. Proportions of Tregswithin donors' and patients' peripheral T cells (n = 9).
y (left) versus isotype control (right). K. Tumor inﬁltrating NK cells gated as CD3−CD56+
m).
Table 3
Patients' T cells are suppressed within the tumor microenvironment and at the systemic level. All % values represent mean ± SEM, n — number of cases analyzed.
Donors'
PBMCs
(n = 9)
Patients'
PBMCs
(n = 9)
GBM
biopsy
(n = 8)
Statistical analysis
% of Th within T cells 65.68 ± 2.10 45.28 ± 7.2 29.43 ±
3.31
Kruskal–Wallis test: p = 0.0005; Dunn's Multiple Comparison Test: p b 0.05 for donors' PBMCs
vs. patients' PBMCs
% of CTLs within T cells 26.32 ± 1.65 37.89 ± 7.05 25.86 ±
2.80
Kruskal–Wallis test: p = 0.2883; Dunn's Multiple Comparison Test: p N 0.05
% of CD28+ cells within CTLs 53.92 ± 7.25 42.60 ± 9.40 9.45 ±
3.70
Kruskal–Wallis test: p = 0.0009; Dunn'sMultiple Comparison Test: p b 0.05 for patients' PBMCs
vs. GBM biopsy
% of CD28+ cells within Th 96.36 ± 1.42 90.13 ± 3.60 39.48 ±
8.68
Kruskal–Wallis test: p = 0.0002; Dunn'sMultiple Comparison Test: p b 0.05 for patients' PBMCs
vs. GBM biopsy
% of CD62L+ cells within CTLs 12.04 ± 2.69 15.03 ± 4.22 0.09 ±
0.09
Kruskal–Wallis test: p = 0.0002; Dunn'sMultiple Comparison Test: p b 0.05 for patients' PBMCs
vs. GBM biopsy
% of CD62L+ cells within Th 28.87 ± 5.31 11.49 ± 3.44 0.14 ±
0.14
Kruskal–Wallis test: p = 0.0001; Dunn'sMultiple Comparison Test: p b 0.05 for patients' PBMCs
vs. GBM biopsy
% of CD56+ cells within CTLs 11.93 ± 2.22 20.78 ± 4.03 4.73 ±
1.54
Kruskal–Wallis test: p = 0.0052; Dunn'sMultiple Comparison Test: p b 0.05 for patients' PBMCs
vs. GBM biopsy
% of CTLA-4+ cells within Th 14.03 ± 1.60 25.63 ± 3.53 18.21 ±
3.91
Kruskal–Wallis test: p = 0.0348; Dunn's Multiple Comparison Test: p b 0.05 for donors' PBMCs
vs. patients' PBMCs
% of CD4+CD25highFoxp3+ Tregs
within T cells
0.43 ± 0.11 0.34 ± 0.13 Not
detected
Wilcoxon signed rank test: p = 0.2859 for donors' PBMCs vs. patients' PBMCs
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MGMT promoter methylation was not correlated with patient survival
and this can be explained by the relatively small sample size and theFig. 4. Tumor inﬁltrating macrophage/microglia present immunotolerized phenotype. Proport
grams showing expression of CD8 and CD4 (B), ILT2,3,4 (C), HLA-E,G (D). Proportions of APCs
showing expression of CD80, CD86, CD40 (F), MICA/B (G), and NKG2D (H) on tumor inﬁltratinfact that we analyzed samples from only one clinical centre. Moreover,
the prognostic value of MGMT promoter methylation has been
questioned (Costa et al., 2010). Future work will be required to validateions of APCs expressing CD8, CD4, ILT2,3,4 and HLA-E,G (A), n = 8. Representative histo-
expressing CD80, CD86, CD40, MICA/B and NKG2D (E), n = 8. Representative histograms
g APCs (ﬁlled histograms —markers, open histograms — isotype control).
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clinics. The expression of CD4 and CD8 markers is not restricted to T
lymphocytes, but has been also described on monocytes, macrophages
and dendritic cells (Gibbings and Befus, 2009). Accordingly, APCs in
our patient cohort did express CD4 and CD8. However, since CD3, CD4
and CD8 were strongly correlated, prognostic signiﬁcance of CD8+
immune cell inﬁltration is related rather to the CTL subpopulation.
However, since GBM still remains the tumor with theworst progno-
sis, we hypothesized that the inefﬁcient immune surveillance and
response occur due to partially impaired functionality of immune cells
recruited to the tumor and/or systemic immunosuppression. The limita-
tion of our study is the lack of functional experiments. However, most
aberrations in immune cells functionality are closely related to their
phenotype. Therefore, our study is highly relevant for translational
research, as it resolves GBM patients' immune status. We observed
that smaller proportions of tumor inﬁltrating T-cells expressed co-
stimulatory receptor CD28 and CD56 – an adhesionmolecule associated
with increased cytotoxicity (Pittet et al., 2000) – compared to those
from patients' peripheral blood. This suggests a decreased cytotoxic
potential and co-stimulation of tumor inﬁltrating T-cells. On the other
hand, T-cells inﬁltrating the tumor display a CD62L negative effector
phenotype (Yang et al., 2011). The majority of tumor inﬁltrating CTLs
express also the NKG2D activating receptor (Bauer et al., 1999). We
observed a decreased proportion of Th cells within patients' peripheral
T-cells. Those cells also expressed higher levels of the inhibitory recep-
tor CTLA-4; however, it tends to decrease within the tumor microenvi-
ronment. On the other hand, an increased proportion of patients' T-cells
expressed CD56. Therefore, we speculate that T-cells entering the brain
are competent, however, once in the tumormicroenvironment, they be-
come suppressed and acquire immunotolerant features. Furthermore,
we observed down-regulation of co-stimulatory pathways that playFig. 5. Tumor inﬁltrating immune cells display impaired expression of co-stimulatorymolecules
CD154 on tumor inﬁltrating T cells and proportions of cells expressing CD40 and CD154 (n = 8)
T-cells andproportions of cells expressingCD70andCD27 (n = 8). C. Representative histogram
ing NKG2D (n = 8) (ﬁlled histograms —markers, open histograms — isotype control).critical roles in immunity. Low expression of CD80 and CD86 on APCs
and down-regulation of their receptor CD28 on T-cells impairs adaptive
immune responses (Smith-Garvin et al., 2009; Ribot et al., 2012). An-
other co-stimulatory pathway affected in our GBMpatients is the absent
interaction of CD40 on APCs with its ligand CD154, normally expressed
on activated T-cells (Foy et al., 1996; Jyothi and Khar, 2000), but absent
in TILs in our GBM patients.
Recently, increasing numbers of reports describe higher propor-
tion and the immunosuppressive action of various Tregs subpopula-
tions in the peripheral blood and tumor microenvironment of
cancer patients including glioma (Fecci et al., 2006; Heimberger
et al., 2008; Sonabend et al., 2008; Wang, 2008; Jacobs et al., 2010).
Our results are in contrast with other studies demonstrating an
increased proportion of CD4+CD25highFoxp3+ cells in the peripheral
blood and tumor microenvironment of GBM patients (Fecci et al.,
2006). This might be explained by the small number of patients we
examined, as in the previous reports the increased Tregs fraction
was not observed for all the patients (Fecci et al., 2006). However,
in the tumor microenvironment we detected CD8+CD28−Foxp3+
Tregs and this ﬁnding might explain modest correlation of CD8+ cell
inﬁltrates with patients' outcome. The CD8+CD28−Foxp3+ Tregs
population has been described to be induced by tumor and to
mediate the tolerization of DCs and non-professional APCs by up-
regulating the expression of inhibitory receptors belonging to the
ILT family and down-regulating co-stimulatory molecules CD40,
CD80 and CD86 (Wang, 2008; Chui and Li, 2009). Within the tumor
inﬁltrating APCs we observed high expression of ILT2, ILT3 and ILT4
and decreased expression of CD40, CD80 and CD86, thus, we specu-
late that a CD8+CD28−Foxp3+ Tregs-mediated immunotolerization
occurs in GBM patients. This tumor immune escape mechanism has
been reported in other cancers (Cortesini, 2007; Filaci et al., 2007)A. Representative histograms showing expression of CD40 on tumor inﬁltrating APCs and
. B. Representative histograms showing expression of CD70 and CD27 on tumor inﬁltrating
s showing expression ofNKG2Don tumor inﬁltratingCTLs andproportions of cells express-
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over, high proportions of APCs were positive for HLA-E and HLA-G
that are ligands for ILT2 and ILT4 (Shiroishi et al., 2003). Furthermore,
we show that APCs may support tumor-driven immunosuppression
via surface expression of CD39 in addition to CD73 expressed on
tumor cells. Ectonucleotidases CD39 and CD73 catalyze two-step degra-
dation of extracellular ATP and ADP. Overexpression of those enzymes
has been reported in cancer (Zhang, 2010) and leads to elevated levelFig. 6. Tumor integratedmechanisms of immune escape vs. potential immunogenicity. Proport
HLA-A,B,C,E,G (B), MICA (C), Fas and FasLigand (D) on tumor cells. Expression of CD39 (E) and
(E) and CD73+ (F) cells within tumor cells and tumor inﬁltrating T-cells andAPCs (n = 8) (ﬁlle
molecular interactions between the tumor and immune cells in the tumor microenvironment
stimulation of signals that support tumor progression, and green arrows indicate activation sigof extracellular adenosine and T-cell and NK cell suppression (Hausler
et al., 2011). Interestingly, the compartmentalization of CD39 and
CD73 expression in our GBM patients suggests, that tumor cells adapt
to the immune status within tumor microenvironment. On the other
hand, a proportion of tumor inﬁltrating APCs expressed MICA,
potentially providing stimulating signal for NK cells through the
NKG2D receptor (Kloss et al., 2008; Eissmann et al., 2010). Interestingly,
APCs also expressed NKG2D receptor. This has not been reported inions of tumor cells expressing HLA-A,B,C,E,G, MICA, Fas and FasL, n = 8 (A). Expression on
CD73 (F) on tumor cells and tumor inﬁltrating T-cells and APCs and proportions of CD39+
d histograms—markers, open histograms— isotype control) G. Schematic summary of the
. Red blunt lines indicate inhibition that supports tumor progression, red arrows indicate
nals that inhibit tumor progression.
Table 4
Concentration of selected cytokines and chemokines in GBM patients' plasma compared to healthy donors' (Wilcoxon signed rank test).
Protein (ﬂex set) Bead position Mean concentration in donors' plasma [pg/ml] ± SEM, n Mean concentration in patients' plasma [pg/ml] ± SEM, n p value
Fas Ligand C6 24.23 ± 2.633, n = 10 10.76 ± 2.423, n = 10 0.004
IL-2 A4 36.61 ± 10.74, n = 10 15.97 ± 6.817, n = 10 0.109
IL-5 A6 5.689 ± 0.7426, n = 10 2.544 ± 1.064, n = 10 0.042
IL-10 B7 7.371 ± 1.628, n = 9 21.77 ± 3.877, n = 9 0.004
IL-12/IL-23p40 E5 24.79 ± 4.735, n = 10 11.72 ± 4.774, n = 10 0.098
MCP-1 D8 115.8 ± 16.26, n = 10 42.19 ± 6.713, n = 10 0.002
Granzyme B D7 36.99 ± 17.67, n = 8 18.51 ± 11.63, n = 8 0.444
IFNγ E7 6.283 ± 2.679, n = 10 6.441 ± 2.765, n = 10 1.000
IL-4 A5 7.182 ± 2.370, n = 9 4.488 ± 1.963, n = 9 0.811
IL-6 A7 3.896 ± 1.494 n = 10 3.075 ± 1.343 n = 10 0.813
IL-13 E6 6.505 ± 2.427 n = 10 5.457 ± 1.882 n = 10 1.000
IL-17A B5 7.296 ± 4.430 n = 9 4.606 ± 4.019 n = 9 0.892
MIP-1α B9 9.700 ± 5.673 n = 10 3.506 ± 3.506 n = 10 0.375
RANTES D4 1773 ± 593.3 n = 10 2806 ± 1699 n = 10 0.492
VEGF B8 17.12 ± 5.121 n = 7 12.09 ± 5.183 n = 7 0.578
The p-values in bold are those that are statistically signiﬁcant.
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sion on activated macrophages plays an important role in immunity
(Diefenbach et al., 2000).
We examined GBM cells for the presence of several surface mole-
cules that are known to activate or inhibit immune cells. Tumor cells
are described to be deﬁcient in MHC class I expression and due to that
they present potent target for NK cell mediated lysis via “missing self”
mechanism (Purdy and Campbell, 2009). To avoid that, they express
non-classical MHC class I molecules HLA-E and HLA-G that bind inhibi-
tory receptors on NK cell's surface (Mittelbronn et al., 2007). However,
in all patients we analyzed, the majority of tumor cells were positive
for HLA-A,B,C that protects them from NK cell-mediated cytotoxicity
by binding inhibitory receptors on NK cells (Purdy and Campbell,
2009). On the other hand, tumor cells were negative for HLA-G and
HLA-E. NK cells represented 2.11% of all tumor inﬁltrating immune
cells and had CD56dimCD16negative phenotype that was previously re-
ported to represent greater activation in some tumors (Levy et al.,
2011). Furthermore upon incubation with tumor target cells, NK cells
have been demonstrated to down-regulate CD16 (Grzywacz et al.,
2007). We also examined GBM cells for the expression of MICA and
MICB — ligands for the activating receptor NKG2D expressed on NK
cells and on a subset of CD8 T-cells. All tumor cells were MICB negative,
however, someof themexpressedMICA, potentially providing stimulat-
ing signals to CTLs and NK cells. In addition we found a proportion of
tumor cells expressing Fas, thus representing potent target for Fas-
mediated apoptosis. Tumor cells did not display FasL surface expression,
which has been described to induce apoptosis of tumor inﬁltrating im-
mune cells (Gomez and Kruse, 2006). These results suggest that GBM
is resistant to autologous NK cell-mediated cytotoxicity due to MHC
class I expression on the tumor cells. However, HLA-A,B,C expression
makes the tumor potentially sensitive to CTL-mediated immune re-
sponse and our ﬁnding of the positive correlation of increased CD3+
and CD8+ inﬁltration into the tumor with improved patients' survival
supports this conclusion. Moreover, due to expression of MICA and ab-
sence of HLA-G and HLA-E surface expression, a proportion of tumor
cells may be sensitive to allogeneic NK cell with KIR receptor–HLA li-
gand mismatch.
In addition, our results reveal that the cytokine balance in GBM
patients is shifted towards anti-inﬂammatory proﬁle. IL-10 is an im-
munosuppressive cytokine, whereas Th1 cytokines induce T-cell
maturation into Th1 type cells that perform cytotoxic functions and
are potentially capable of defending against cancer (Kidd, 2003). It
has been described that the cytokine signaling in the periphery and
in the brain inﬂuences each other (Quan and Herkenham, 2002). In
this context, there may be a link between elevated IL-10 in patients'
plasma and overexpression of ILT receptors on tumor inﬁltrating im-
mune cells, as such a correlation has already been suggested (Chui
and Li, 2009).In conclusion, our study showed beneﬁcial role of immune cell inﬁl-
tration into the tumor in GBM patients, despite multiplemechanisms of
tumor immune escape. Our detailed investigation identiﬁed potent tar-
gets for enhancing immune response and/or overriding tumor-driven
immunosuppression. An example of such a target is the inhibitory re-
ceptor CTLA-4. Ipilimumab, the anti-CTLA-4 antibody, has already
been successfully applied in melanoma patients (Hodi et al., 2010;
Robert et al., 2011) and in-vivo studies showed promising results in
brain tumor (Fecci et al., 2007). In GBM patients we observed
upregulated expression of CTLA-4 in peripheral Th cells, thus we hy-
pothesize that the therapy targeting this receptormay be also applicable
in GBM as an adjuvant treatment.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jneuroim.2013.08.013.
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